PD, PK, and Safety of ALTO-203 in Patients With MDD
Public ClinicalTrials.gov record NCT06391593. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Double-Blind, Single and Multiple Dose Study to Determine Pharmacodynamic Markers, Pharmacokinetic Parameters, and Safety of ALTO-203 in Patients With Major Depressive Disorder
Study identification
- NCT ID
- NCT06391593
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Alto Neuroscience
- Industry
- Enrollment
- 69 participants
Conditions and interventions
Conditions
Interventions
- ALTO-203 25 μg Drug
- ALTO-203 75 μg Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 25 Years to 64 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 24, 2024
- Primary completion
- Apr 13, 2025
- Completion
- Apr 20, 2025
- Last update posted
- Apr 16, 2026
2024 – 2025
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 4058 | Tucson | Arizona | 85704 | — |
| Site 4082 | Oceanside | California | 92056 | — |
| Site 4023 | Torrance | California | 90504 | — |
| Site 4059 | Clermont | Florida | 34711 | — |
| Site 4005 | Orlando | Florida | 32801 | — |
| Site 4031 | Atlanta | Georgia | 30030 | — |
| Site 4054 | Pikesville | Maryland | 21208 | — |
| Site 4036 | Las Vegas | Nevada | 89121 | — |
| Site 4022 | Marlton | New Jersey | 08053 | — |
| Site 4134 | Princeton | New Jersey | 08540 | — |
| Site 4075 | Westlake | Ohio | 44145 | — |
| Site 4040 | Austin | Texas | 78737 | — |
| Site 4072 | Houston | Texas | 77081 | — |
| Site 4007 | Clinton | Utah | 84015 | — |
| Site 4033 | Bellevue | Washington | 98007 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06391593, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 16, 2026 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06391593 live on ClinicalTrials.gov.